News

27.02.2020 |

Gene-editing regulation not the biggest hurdle for SMEs in EU, says academic

The argument that excessive regulation adversely affects small and medium enterprises (SMEs) does not stand up to scrutiny, according to molecular geneticist Dr Michael Antoniou, head of the gene expression and therapy group at King’s College London.

The regulatory approval process for new biotech crop varieties is often said to be unduly slow and expensive, presenting an important barrier for biotech SMEs.

The chair of the agriculture committee (AGRI) MEP, Norbert Lins, recently told EURACTIV.com that it is much easier for larger companies to implement new GM legislation, but it’s the smaller ones that are most affected by the recent gene-editing ruling.

Zurück zu den Meldungen

EnglishFranceDeutsch